The Effect of Biomarkers of Inflammation on Graft Function in Kidney Transplantation
Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05753488
Collaborator
(none)
100
1
7
14.2
Study Details
Study Description
Brief Summary
The aim of the study was to investigate the relationship of inflammation markers with postoperative graft function and mortality in patients undergoing kidney transplantation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
The Effect of Biomarkers of Inflammation on Graft Function
Anticipated Study Start Date
:
Mar 1, 2023
Anticipated Primary Completion Date
:
Aug 1, 2023
Anticipated Study Completion Date
:
Oct 1, 2023
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
ınflammation
|
Diagnostic Test: graft function
renal transplantation
|
non inflammation
|
Diagnostic Test: graft function
renal transplantation
|
Outcome Measures
Primary Outcome Measures
- RDW [baseline]
Red Cell Distribution Width
- PNI [baseline]
prognostic nutrition index (PNI) calculated as 10 × serum albumin (g/dl) + 0.005 × total lymphocyte count (per mm3)
- De Ritis [baseline]
De Ritis described the ratio between the serum levels of aspartate transaminase (AST) and alanine transaminase (ALT)
- graft function [through study completion, an average of 1 year]
Eligibility Criteria
Criteria
Ages Eligible for Study:
12 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- patients underwent renal transplantation
Exclusion Criteria:
- patient refusal
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Ankara City Hospital | Ankara | Turkey | 06800 |
Sponsors and Collaborators
- Ankara City Hospital Bilkent
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
ismail aytaç,
Principal investigator,
Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT05753488
Other Study ID Numbers:
- E1-23-3250
First Posted:
Mar 3, 2023
Last Update Posted:
Mar 3, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: